Pavan Cheruvu, Sio Gene Therapies CEO
Sio Gene Therapies posts positive PhI/II data in rare pediatric disease, the first readout since its name change
A little over a month after a full company rebrand, the Biotech Formerly Known as Axovant has its first data readout under its new moniker …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
